Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic Melanoma and Predictive Value of Angiogenic Markers.
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Bevacizumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 29 Jul 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
- 29 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 May 2010 Planned end date changed from 1 May 2010 to 1 May 2011 as reported by ClinicalTrials.gov.